In those nations, MAID is available to a wider universe of pained people, not just those with fewer than six months to live.

Doctors are using a new gene therapy drug from the US, hoping to extend Ms Sabrina's lifespan. Read more at straitstimes.com. Read more at straitstimes.com.

Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023.

Both TEGSEDI and WAYLIVRA are legacy assets that were originally brought to the EU market via an Ionis subsidiary, Akcea Therapeutics. Ionis later acquired Akcea, and both products are now distributed ...

In this article, we will look at the 13 Cheap Healthcare Stocks with Huge Upside Potential. On July 8, Kate Moore, Citi Wealth CIO, appeared on CNBC’s ‘Squawk Box’ to talk about the recent rally in ...

Denali Therapeutics, Inc. DNLI announced that the FDA has accepted for review its biologics license application (BLA) for ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing.

As the saying goes, “If you don’t laugh, you’ll cry.” Biogen and ad agency 21Grams took that mantra to heart with their Gold Pharma Lions–winning social media campaign, “Friedreich’s ...

BEIJING, June 26, 2025 /PRNewswire/ -- SineuGene Therapeutics, a clinical-stage biotechnology company focused on gene therapies for neurological diseases, announced that the U.S. Food and Drug ...

Biogen on Monday said the phase 3 study will evaluate the efficacy and safety of felzartamab compared to the immunosuppressive drug tacrolimus in adults with PMN, with a readout expected in 2029.